A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
Public ClinicalTrials.gov record NCT03560245. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized double-blind Placebo-controlled, Phase 2 study comparing bryostatin to placebo for the treatment of moderately severe to severe Alzheimer's disease in subjects not receiving memantine treatment. The study is 15 weeks in duration, including a safety and efficacy evaluation 30 days after the last dose of study drug. Subjects will receive 7 doses of study drug during the study. The primary efficacy endpoint is defined as the change from baseline to Week 13 in the Severe Impairment Battery (SIB) total score.
Study identification
- NCT ID
- NCT03560245
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 108 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 55 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 20, 2018 (Actual)
- Primary completion
- Jul 25, 2019 (Actual)
- Completion
- Jul 25, 2019 (Actual)
- Last update posted
- Oct 1, 2020
2018 – 2019
United States locations
- U.S. sites
- 28
- U.S. states
- 12
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Neuro Pain Medical Center | Fresno | California | 93710 | — |
| Nader Pharmacology Research Institute | Los Alamitos | California | 90720 | — |
| Syrentis Clinical Research | Santa Ana | California | 92705 | — |
| Southern California Research, LLC | Simi Valley | California | 93065 | — |
| JEM Research | Atlantis | Florida | 33462 | — |
| Brain Matters Research | Delray Beach | Florida | 33445 | — |
| MD Clinical | Hallandale | Florida | 33009 | — |
| Alzheimer's Research and Treatment Center | Lake Worth | Florida | 33449 | — |
| Miami Jewish Health / Stein Gerontological Institute | Miami | Florida | 33137 | — |
| Phoenix Medical Research | Miami | Florida | 33165 | — |
| Miami Dade Medical Research Institute, LLC | Miami | Florida | 33176 | — |
| Medical Research Group of Central Florida | Orange City | Florida | 32763 | — |
| Bioclinica Research | Orlando | Florida | 32806 | — |
| Anchor Neuroscience | Pensacola | Florida | 32502 | — |
| Stedman Clinical Trials | Tampa | Florida | 33613 | — |
| Bioclinica Research | The Villages | Florida | 32162 | — |
| Atlanta Center for Medical Research | Atlanta | Georgia | 30331 | — |
| Medical Research & Health Education Foundation | Columbus | Georgia | 31909 | — |
| Alexian Brothers Neuroscience Institute | Elk Grove Village | Illinois | 60007 | — |
| Lake Charles Clinical Trials | Lake Charles | Louisiana | 70629 | — |
| Alzheimer's Disease Center | Quincy | Massachusetts | 02169 | — |
| Millennium Psychiatric Associates | Creve Coeur | Missouri | 63141 | — |
| The Cognitive and Research Center of New Jersey | Springfield | New Jersey | 07801 | — |
| Neurological Associates of Albany, PC | Albany | New York | 12208 | — |
| Burke Rehabilitation Hospital | White Plains | New York | 10605 | — |
| Alzheimer's Memory Center | Charlotte | North Carolina | 28270 | — |
| Insight Clinical Trials, LLC | Shaker Heights | Ohio | 44122 | — |
| Memory Health Center at Summit Research Network | Portland | Oregon | 97210 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03560245, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2020 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03560245 live on ClinicalTrials.gov.